Safety aspects of gadofosveset in clinical practice - analysis of acute and long-term complications

Magnetic Resonance Imaging

Volumn 32, Issue 5, 2014, Pages 570-573

  Alhadad, Alaa ^a   Åkesson, Michael ^a   Lehti, Leena ^a,b   Leander, Peter ^a,b   Sterner, Gunnar ^a,b   Åkeson, Per ^a   Wassélius, Johan ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Blood pool contrast medium; Gadofosveset; Gadolinium based contrast medium; Magnetic resonance imaging; Nephrogenic systemic fibrosis

Indexed keywords

GADOFOSVESET; CONTRAST MEDIUM; GADOLINIUM; ORGANOMETALLIC COMPOUND;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL PRACTICE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SKIN DISEASE; VERY ELDERLY; ACUTE DISEASE; CHEMICALLY INDUCED; CHRONIC DISEASE; DIAGNOSTIC USE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; RISK ASSESSMENT; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHRONIC DISEASE; CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; ORGANOMETALLIC COMPOUNDS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 84899064662     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2014.02.012     Document Type: Article

References (19)

1. Cowper S.E., Robin H.S., Steinberg S.M., Su L.D., Gupta S., LeBoit P.E. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000, 356:1000-1001.
2. Thomsen H.S. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006, 16:2619-2621.
3. Chrysochou C., Power A., Shurrab A.E., Husain S., Moser S., Lay J., et al. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol 2010, 5(3):484-489.
4. Abujudeh H.H., Rolls H., Kaewlai R., Agarwal S., Gebreananya Z.A., Saini S., et al. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging 2009, 30(6):1335-1340.
5. Alhadad A., Sterner G., Svensson Å., Alhadad H., Leander P. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden. Scand J Urol Nephrol 2012, 46(1):48-53.
6. Parmelee D.J., Walovitch R.C., Ouellet H.S., Lauffer R.B. Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Invest Radiol 1997, 32(12):741-747.
7. Lauffer R.B., Parmelee D.J., Dunham S.U., Ouellet H.S., Dolan R.P., Witte S., et al. MS-325: albumin-targeted contrast agent for MR angiography. Radiology 1998, 207(2):529-538.
8. Grist T.M., Korosec F.R., Peters D.C., Witte S., Walovitch R.C., Dolan R.P., et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology 1998, 207(2):539-544.
9. Bluemke D.A., Stillman A.E., Bis K.G., Grist T.M., Baum R.A., D'Agostino R., et al. Carotid MR angiography: phase II study of safety and efficacy for MS-325. Radiology 2001, 219(1):114-122.
10. Sharafuddin M.J., Stolpen A.H., Dang Y.M., Andresen K.J., Roh B.S. Comparison of MS-325- and gadodiamide-enhanced MR venography of iliocaval veins. J Vasc Interv Radiol 2002, 13(10):1021-1027.
11. Perreault P., Edelman M.A., Baum R.A., Yucel E.K., Weisskoff R.M., Shamsi K., et al. MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial. Radiology 2003, 229(3):811-820. [Epub 2003 Oct 30].
12. Rapp J.H., Wolff S.D., Quinn S.F., Soto J.A., Meranze S.G., Muluk S., et al. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography-multicenter comparative phase III study. Radiology 2005, 236(1):71-78.
13. Goyen M., Edelman M., Perreault P., O'Riordan E., Bertoni H., Taylor J., et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology 2005, 236(3):825-833.
14. Steger-Hartmann T., Graham P.B., Müller S., Schweinfurth H. Preclinical safety assessment of Vasovist (gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography. Invest Radiol 2006, 41(5):449-459.
15. Tyeklar Z., Dunham S.U., Midelfort K., Scott D.M., Sajiki H., Ong K., et al. Structural, kinetic, and thermodynamic characterization of the interconverting isomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem 2007, 46(16):6621-6631.
16. Caravan P., Parigi G., Chasse J.M., Cloutier N.J., Ellison J.J., Lauffer R.B., et al. Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem 2007, 46(16):6632-6639.
17. Shamsi K., Yucel E.K., Chamberlin P. A summary of safety of gadofosveset (MS-325) at 0.03mmol/kg body weight dose: phase II and phase III clinical trials data. Invest Radiol 2006, 41(11):822-830.
18. Levey A.S., Coresh J., Greene T., Stevens L.A., Zhang Y.L., Hendriksen S., et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145:247-254.
19. Nyman U., Grubb A., Sterner G., Björk J. The CKD-EPI and MDRD equations to estimate GFR. Validation in the Swedish Lund-Malmö Study cohort. Scand J Clin Lab Invest 2011, 71:129-138.